| 110 / 1 |
Use of likelihood estimates for variances for the design and evaluation of multiregional clinical trials with heterogeneous variances
|
|
2022-07-25 |
| 109 / 2 |
Impact of efavirenz mid-dose plasma concentration on long-term weight change among virologically suppressed people living with HIV
|
|
2022-07-19 |
| 109 / 2 |
Tolerance interval testing for assessing accuracy and precision simultaneously
|
|
2022-07-19 |
| 109 / 1 |
Operational experiences in China and statistical issues on the conduct of clinical trials during the COVID-19 pandemic
|
|
2022-05-09 |
| 108 / 2 |
Use of a tolerance interval approach as a statistical quality control tool for traditional Chinese medicine
|
|
2022-05-09 |
| 109 / 1 |
Use of a two‐sided tolerance interval in the design and evaluation of biosimilarity in clinical studies
|
|
2022-05-09 |
| 106 / 1 |
Use of interval estimations in design and evaluation of multiregional clinical trials with continuous outcomes
|
|
2022-05-09 |
| 106 / 1 |
Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy
|
|
2022-05-09 |
| 104 / 2 |
Differences in health‐related quality of life between European and Asian patients with hepatocellular carcinoma
|
|
2022-05-09 |
| 105 / 2 |
An approach for sample size determination of average bioequivalence based on interval estimation
|
|
2022-05-09 |
| 103 / 2 |
Quality of life changes in patients undergoing treatment for hepatocellular carcinoma
|
|
2022-05-09 |
| 103 / 1 |
Sample size determination for individual bioequivalence inference
|
|
2022-05-09 |
| 102 / 2 |
Sample size determination for within‐device precision
|
|
2022-05-09 |
| 101 / 1 |
Statistical Methods for Bridging Studies
|
|
2022-05-09 |
| 100 / 1 |
International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-life questionnaire HCC18
|
|
2022-05-09 |
| 099 / 2 |
An inferential procedure for the probability of passing the USP dissolution test
|
|
2022-05-09 |
| 098 / 2 |
Quality of life of patients with oesophageal cancer in Taiwan: validation and application of the Taiwan Chinese (Mandarin) version of the EORTC QLQ-OES18: a brief communication
|
|
2022-05-09 |
| 098 / 2 |
Quality of life of patients with ovarian cancer in Taiwan: validation and application of the Taiwan Chinese version of the EORTC QLQ‐OV28
|
|
2022-05-09 |
| 110 / 2 |
Three-Stage Pooled Plasma Hepatitis C Virus RNA Testing for the Identification of Acute HCV Infections in At-Risk Populations
|
|
2023-07-06 |
| 111 / 1 |
Low Hepatitis B Core-Related Antigen Levels Correlate Higher Spontaneous Seroclearance of HBsAg in Chronic Hepatitis B Patients with High HBsAg Levels
|
|
2024-07-03 |
| 112 / 1 |
Muscle strength in ostensibly healthy non-diabetic subjects
|
|
2024-07-16 |
| 112 / 1 |
HBcrAg-based risk score performs better than the HBV DNA-based scores for HCC prediction in grey zone patients who are HBeAg-negative
|
|
2024-07-16 |
| 112 / 2 |
A statistical method for protocol modifications with heterogeneous population variances
|
|
2024-08-05 |